Mirae Asset Healthcare Fund Direct Growth

Sectoral / ThematicEquityVery High risk Rank 22 of 157

NAV · Direct-Growth

₹51.60+0.18+0.36%

As of 18 Aug 2026 · AMFI

NAV growth+18.8%

Aug ’25Aug ’26

Arthkar verdictSolid on the numbers

Returns

Beats category

1Y, 3Y, 5Y all ahead

Cost

Average

0.44% vs NaN% peers

Volatility

Below average

16.2% vs 16.3% cat (3Y)

Consistency

Steady

positive in 6 of 8 years

Beats its Sectoral / Thematic category on 1Y, 3Y & 5Y — and has been steadier than peers.

1Y return

+18.8%

+9.3 vs cat

3Y CAGR

+23.1%

+5.9 vs cat

5Y CAGR

+15.9%

+1.2 vs cat

AUM

₹3.1K Cr

fund size

Expense

0.44%

direct plan

Volatility 3Y

16.2%

▼ vs 16.3%

Go deeper on Mirae Asset Healthcare Fund Direct Growth

Two data-only views, computed from this fund's real NAV history — no projections.

Mirae Asset Healthcare Fund Direct Growth SIP returnsWhat ₹1,000–₹25,000/month actually became, 3 to 20 years — real results, with drawdowns and an FD comparison.Mirae Asset Healthcare Fund Direct Growth real oddsYour real chances over every start date in history — how often it made money and beat a fixed deposit.

In plain English

Mirae Asset Healthcare Fund Direct Growth is a Sectoral / Thematic scheme from Mirae Asset. The portfolio is ~99% in equities. Long-run track record: about 15.9% CAGR over 5 years. Volatility is typical for equity — 20–30 % drawdowns happen during market stress. Worst historical drawdown: -20% in Mar 2020, recovered in 1 months. Wrong fit if you need this money in less than 7 years.

Auto-generated from holdings, returns and risk data. No paid placement, no copy-pasted boilerplate.

NAV history

Showing Direct · Growth · INF769K01ED6

NAV (Direct-Growth)

₹51.6020

Last 1Y

+18.82%

Aug 25Min ₹40.46 · Max ₹51.97 · 247 ptsAug 26

Drawdown stories

The crashes you should know about — and how long the fund took to recover.

Mar 2020

-20.0%

Peak ₹12.43 on 20 Feb 2020 → trough ₹9.95 on 23 Mar 2020 (1 months down).

Recovered in 1 months· 8 Apr 2020

Jun 2022

-18.5%

Peak ₹25.47 on 3 Jan 2022 → trough ₹20.76 on 17 Jun 2022 (6 months down).

Recovered in 13 months· 11 Jul 2023

Feb 2025

-15.9%

Peak ₹44.15 on 2 Jan 2025 → trough ₹37.13 on 28 Feb 2025 (2 months down).

Recovered in 5 months· 17 Jul 2025

Oct 2019

-12.1%

Peak ₹11.28 on 7 Sept 2018 → trough ₹9.92 on 7 Oct 2019 (13 months down).

Recovered in 3 months· 3 Jan 2020

Computed from the full NAV history. We show drawdowns deeper than 10%, sorted by depth.

Honesty score

A 1–5 grade on the dimensions other sites won't surface — expense bloat, AUM bloat, concentration, mandate compliance.

Honesty score

4 / 5

Solid scheme on the dimensions we check. No red flags.

Expense ratio
0.44% — well below typical 1% for equity.
AUM size
₹3.1K Cr.
Sector concentration
Top 3 sectors = 99.9% — heavy concentration risk.

Computed from expense ratio, AUM, sector concentration and SEBI mandate compliance. No paid review.

Performance

Returns for various periods, with category average and peer rank.

Period	Returns	Category avg	Rank
1W	-0.70%	-0.40%	172/ 286
1M	+2.80%	+2.47%	132/ 286
3M	+8.06%	+8.01%	129/ 286
6M	+19.80%	+6.33%	17/ 278
YTD	+20.39%	+6.03%	19/ 273
1Y	+18.82%	+9.52%	40/ 258
2Y	+12.45%	+5.82%	22/ 203
3Y	+23.09%	+17.18%	22/ 157
5Y	+15.91%	+14.76%	42/ 125
7Y	+26.27%	+18.88%	5/ 104

Portfolio composition

Asset allocation

Equity99.36%
Cash0.64%
Other0.01%

By market cap

Large cap35.49%
Mid cap34.79%
Small cap26.90%
Others2.82%

Concentration

Holdings

Avg market cap

₹73.6K Cr

Top 10 stocks

61.10%

Top 5 stocks

40.10%

Top 3 sectors

99.92%

Top holdings

Top 15 positions by weight, latest disclosure.

#InstrumentSectorWeight

1
Sun Pharmaceuticals Industries Ltd
—12.20%
1
Sun Pharmaceuticals Industries Ltd
—12.20%
2
Divi's Laboratories Ltd
—7.93%
2
Divi's Laboratories Ltd
—7.93%
3
Glenmark Pharmaceuticals Ltd
—6.94%
3
Glenmark Pharmaceuticals Ltd
—6.94%
4
J.B. Chemicals & Pharmaceuticals Ltd
—6.88%
4
J.B. Chemicals & Pharmaceuticals Ltd
—6.88%
5
Apollo Hospitals Enterprise Ltd
—6.15%
5
Apollo Hospitals Enterprise Ltd
—6.15%
6
Lupin Ltd
—5.06%
6
Lupin Ltd
—5.06%
7
Aurobindo Pharma Ltd
—4.32%
7
Aurobindo Pharma Ltd
—4.32%
8
Dr Reddy's Laboratories Ltd
—4.31%

Fundamentals (vs category)

Portfolio-weighted ratios, compared with the category average.

MetricFundCategory avgDiff

P/E ratio40.4741.09-0.62
P/B ratio5.675.83-0.16
Price / Sales5.885.71+0.17
Price / Cash Flow29.9430.54-0.60
Dividend yield0.55%0.63%-0.08
Return on equity (ROE)14.98%16.57%-1.59

Risk metrics

Standard deviation, Sharpe, Sortino, Beta — all vs category average.

Metric1Y3Y5YCat 1YCat 3YCat 5Y

Standard deviation
Volatility — lower means steadier returns.
17.5816.4315.7314.9216.2915.44
Sharpe ratio
Risk-adjusted return — higher is better.
0.701.070.660.480.980.58
Sortino ratio
Like Sharpe but only counts downside volatility.
1.271.951.110.831.710.94
Beta
1 = moves with the market. <1 = less volatile.
0.920.970.970.940.950.94

Peers in Sectoral / Thematic

Other schemes in the same SEBI category, ranked by AUM.

Peer fundAUM1Y3Y CAGRExpense

Peers in same SEBI category, ranked by AUM. Compare any →

Available plans & options

PlanOptionFull nameISIN

Click a plan to see its NAV and chart above. Direct plans have lower expense ratios than Regular — same portfolio, more of the return stays with you.

NEW

See your SIP through Indian market history

Pick a fund and a start year — get a 60-second cinematic replay of every crash, boom, and headline with your money in it. Real NAV data, no “assumed 12%” lies.

Try Wealth Time Machine

AI · Free

Find what's really inside your funds

Upload your CAS PDF — get instant stock concentration, hidden fund overlap, sector risk, and 3 key insights, written by AI in plain English.

Run Portfolio X-Ray